Fosun Pharmaceutical (01652.HK): "Metformin Empagliflozin Tablets (I)" approved for market launch

The Zhitong Finance APP news, Fosun Pharma (01652.HK) announced that the company's research and development of "Metformin Englitazone Tablets (I)" has been approved by the China National Medical Products Administration for marketing application, approved for the treatment of the following diseases: This product, in combination with diet control and exercise, is suitable for adult patients with type 2 diabetes who are currently receiving treatment with Englitazone and Metformin hydrochloride, to improve blood glucose control in these patients.